4-Epichlortetracycline hydrochloride, can be used as secondary standard

Name: 4-Epichlortetracycline hydrochloride, can be used as secondary standard
SKU: FSA268231000

4-Epichlortetracycline hydrochloride, CAS # 14297-93-9, is a broad-spectrum, bacteriostatic antibiotic of the tetracycline antibiotic family.

Change view

Quantity:

100 mg

Packaging:

Glass bottle

Catalog number FSA268231000

View Price:

Quantity:

100 mg

Packaging:

Glass bottle

Request bulk or custom format

Specifications

Chemical Name or Material4-Epichlortetracycline hydrochloride

Name Note97%

CAS101342-45-4

CAS Min %96.0

Health Hazard 1GHS Signal Word: Warning

This Thermo Scientific Chemicals brand product was originally part of the Acros Organics product portfolio. Some documentation and label information may refer to the legacy brand. The original Acros Organics product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.

General description

• 4-Epichlortetracycline is the hydrochloride salt of 4-Epichlortetracycline, a tetracycline ring structure with a chloride substitution

• 4-Epichlortetracycline hydrochloride (4-Epi-chlortetracycline) is an epimer of chlortetracycline

• 4-Epichlortetracycline suppresses neutrophil activity and dampens the immune response

• Acts as an aminoacyl-tRNA analog to disrupt polypeptide synthesis, reducing bacterial growth Applications

• Can be used for in vitro research on cancer and inflammatory mechanisms

• Intended for use as a selective agent and secondary standard

RUO – Research Use Only

General References:

Armstrong, A.W.; Hekmatjah, J.; Kircik, L.H. Oral Tetracyclines and Acne: A Systematic Review for Dermatologists. J Drugs Dermatol. 2020, 19(11), s6-s13.
Liou, J.M.; Chen, C.C.; Chang, C.M.; Fang, Y.J.; Bair, M.J.; Chen, P.Y.; Chang, C.Y.; Hsu, Y.C.; Chen, M.J.; Chen, C.C.; Lee, J.Y.; Yang, T.H., Luo, J.C.; Chen, C.Y.; Hsu, W.F.; Chen, Y.N.; Wu, J.Y.; Lin, J.T.; Lu, T.P.; Chuang, E.Y.; El-Omar, E.M.; Wu, M.S. Taiwan Gastrointestinal Disease and Helicobacter Consortium. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial. Lancet Infect Dis. 2019,(10), 1109-1120.